	US 12,241,105 B2
	Recombinant microorganisms and uses therefor
Nicholas Alexander Fackler, Chicago, IL (US); Sean Dennis Simpson, Evanston, IL (US); Michael Koepke, Chicago, IL (US); and Stephanie Rhianon Jones, Evanston, IL (US)
Assigned to LanzaTech, Inc., Skokie, IL (US)
Filed by LanzaTech, Inc., Skokie, IL (US)
Filed on Jul. 18, 2022, as Appl. No. 17/813,240.
Claims priority of provisional application 63/223,952, filed on Jul. 20, 2021.
Prior Publication US 2023/0129301 A1, Apr. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12P 19/34 (2006.01); C12N 1/20 (2006.01); C12N 1/32 (2006.01); C12P 7/04 (2006.01); G16B 5/10 (2019.01); G16B 20/50 (2019.01)

CPC C12P 19/34 (2013.01) [C12N 1/20 (2013.01); C12N 1/32 (2013.01); C12P 7/04 (2013.01); G16B 5/10 (2019.02); G16B 20/50 (2019.02)]

8 Claims

1. A genetically engineered C1-fixing microorganism capable of co-producing at least one target product and a nanobody comprising an exogenous nucleic acid encoding a nanobody gene, wherein the genetically engineered C1-fixing microorganism has improved carbon flux through acetoacetyl-CoA compared to a parental microorganism, wherein the nanobody gene is VHH-72 SARS Cov2.